View Item 

Show simple item record

The association of prescription opioid use with incident cancer: A Surveillance, Epidemiology, and End Results‐Medicare population‐based case‐control study

dc.contributor.authorHavidich, Jeana E.
dc.contributor.authorWeiss, Julie E.
dc.contributor.authorOnega, Tracy L.
dc.contributor.authorLow, Ying H.
dc.contributor.authorGoodrich, Martha E.
dc.contributor.authorDavis, Mathew A.
dc.contributor.authorSites, Brian D.
dc.date.accessioned2021-05-12T17:27:06Z
dc.date.available2022-06-12 13:27:04en
dc.date.available2021-05-12T17:27:06Z
dc.date.issued2021-05-15
dc.identifier.citationHavidich, Jeana E.; Weiss, Julie E.; Onega, Tracy L.; Low, Ying H.; Goodrich, Martha E.; Davis, Mathew A.; Sites, Brian D. (2021). "The association of prescription opioid use with incident cancer: A Surveillance, Epidemiology, and End Results‐Medicare population‐based case‐control study." Cancer (10): 1648-1657.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/167541
dc.publisherWiley Periodicals, Inc.
dc.publisherThe Commonwealth Fund
dc.subject.othercancer
dc.subject.otherMedicare
dc.subject.otheropioids
dc.subject.otherprescription opioids
dc.subject.otherSurveillance
dc.subject.otherEpidemiology
dc.subject.otherand End Results (SEER)‐Medicare
dc.titleThe association of prescription opioid use with incident cancer: A Surveillance, Epidemiology, and End Results‐Medicare population‐based case‐control study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167541/1/cncr33285.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167541/2/cncr33285_am.pdf
dc.identifier.doi10.1002/cncr.33285
dc.identifier.sourceCancer
dc.identifier.citedreferenceShavit Y, Ben‐Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004; 11: 255 ‐ 260.
dc.identifier.citedreferenceCronin‐Fenton DP, Heide‐Jorgensen U, Ahern TP, et al. Opioids and breast cancer recurrence: a Danish population‐based cohort study. Cancer. 2015; 121: 3507 ‐ 3514.
dc.identifier.citedreferenceSingleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ‐opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014; 113 ( suppl 1 ): i103 ‐ i108.
dc.identifier.citedreferenceWang K, Qu X, Wang Y, Shen H, Liu Q, Du J. Effect of mu agonists on long‐term survival and recurrence in nonsmall cell lung cancer patients. Medicine (Baltimore). 2015; 94: e1333.
dc.identifier.citedreferenceMaher D, Wong W, White P, et al. Association of increased postoperative opioid administration with non‐small‐cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014; 113 ( suppl 1 ): i88 ‐ i94.
dc.identifier.citedreferenceLennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ‐opioid receptor in human non‐small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012; 116: 857 ‐ 867.
dc.identifier.citedreferenceCata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non‐small cell lung cancer resection. Cancer Med. 2014; 3: 900 ‐ 908.
dc.identifier.citedreferenceSingleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: a new target for cancer therapy? Cancer. 2015; 121: 2681 ‐ 2688.
dc.identifier.citedreferenceBrittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer. 1996; 77: 1226 ‐ 1243.
dc.identifier.citedreferenceVivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012; 12: 239 ‐ 252.
dc.identifier.citedreferenceGuillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016; 17: 1025 ‐ 1036.
dc.identifier.citedreferenceWhiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995; 7: 704 ‐ 710.
dc.identifier.citedreferenceYeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine‐enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 1995; 83: 500 ‐ 508.
dc.identifier.citedreferenceTai LH, de Souza CT, Belanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery‐induced dysfunction in natural killer cells. Cancer Res. 2013; 73: 97 ‐ 107.
dc.identifier.citedreferenceNguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014; 113 ( suppl 1 ): i4 ‐ i13.
dc.identifier.citedreferenceLennon FE, Moss J, Singleton PA. The μ‐opioid receptor in cancer progressions there a direct effect? Anesthesiology. 2012; 116: 940 ‐ 945.
dc.identifier.citedreferenceBeilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg. 1996; 82: 492 ‐ 497.
dc.identifier.citedreferenceBuckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti‐tumour activity of serum from women undergoing breast cancer surgery: a pilot study. Br J Anaesth. 2014; 113 ( suppl 1 ): i56 ‐ i62.
dc.identifier.citedreferenceEisenstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol. 1998; 83: 36 ‐ 44.
dc.identifier.citedreferenceMaher DP, Walia D, Heller NM. Suppression of human natural killer cells by different classes of opioids. Anesth Analg. 2019; 128: 1013 ‐ 1021.
dc.identifier.citedreferenceMellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol. 1998; 83: 19 ‐ 28.
dc.identifier.citedreferenceMatta S, Saphier D, Dunn AJ. The brain‐immune axis and drugs of abuse cytokines as mediators of infection‐induced stress. J Neuroimmunol. 1996; 69: P25 ‐ P39.
dc.identifier.citedreferenceNeeman E, Zmora O, Ben‐Eliyahu S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res. 2012; 18: 4895 ‐ 4902.
dc.identifier.citedreferenceNeeman E, Ben‐Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013; 30 ( suppl ): S32 ‐ S40.
dc.identifier.citedreferenceFarooqui M, Li Y, Rogers T, et al. COX‐2 inhibitor celecoxib prevents chronic morphine‐induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007; 97: 1523 ‐ 1531.
dc.identifier.citedreferenceFreedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007; 165: 1424 ‐ 1433.
dc.identifier.citedreferenceNasrollahzadeh D, Kamangar F, Aghcheli K, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high‐risk area of Iran. Br J Cancer. 2008; 98: 1857 ‐ 1863.
dc.identifier.citedreferenceDu KN, Feng L, Newhouse A, et al. Effects of intraoperative opioid use on recurrence‐free and overall survival in patients with esophageal ade7nocarcinoma and squamous cell carcinoma. Anesth Analg. 2018; 127: 210 ‐ 216.
dc.identifier.citedreferenceDavis K, Schoen C, Bandeali F. Medicare: 50 Years of Ensuring Coverage and Care. The Commonwealth Fund; 2015. Accessed July 21, 2019. https://www.commonwealthfund.org/publications/fund‐reports/2015/apr/medicare‐50‐years‐ensuring‐coverage‐and‐care
dc.identifier.citedreferenceWorld Health Organization (WHO). WHO Cancer Fact Sheets. Accessed June 6, 2019. https://www.who.int/news‐room/fact‐sheets/detail/cancer
dc.identifier.citedreferenceWorld Health Organization (WHO). Number of New Cases, 2018. Accessed June 6, 2019. http://gco.iarc.fr/today/data/factsheets/cancers/39‐All‐cancers‐fact‐sheet.pdf
dc.identifier.citedreferenceIslami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018; 68: 31 ‐ 54.
dc.identifier.citedreferenceEngels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Practice of epidemiology use of Surveillance, Epidemiology, and End Results‐Medicare data to conduct case‐control studies of cancer among the US elderly. Am J Epidemiol. 2011; 174: 860 ‐ 870.
dc.identifier.citedreferenceMahale P, Torres HA, Kramer JR, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry‐based case‐control study. Cancer. 2017; 123: 1202 ‐ 1211.
dc.identifier.citedreferenceKlabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258 ‐ 1267.
dc.identifier.citedreferenceMathew B, Lennon FE, Siegler JH, et al. Novel role of the mu opioid receptor in lung cancer progression: a laboratory study. Anesth Analg. 2011; 112: 558 ‐ 567.
dc.identifier.citedreferenceBortsov AV, Millikan RC, Belfer I, Boortz‐Marx RL, Arora H, McLean SA. μ‐Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012; 116: 896 ‐ 902.
dc.identifier.citedreferenceWeingaertner IR, Koutnik S, Ammer H. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. PLoS One. 2013; 8: e53510.
dc.identifier.citedreferenceWang S, Li Y, Liu XD, Zhao CX, Yang KQ. Polymorphism of A118G in μ‐opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013; 18: 666 ‐ 669.
dc.identifier.citedreferenceZhang YF, Xu QX, Liao LD, et al. Association of mu‐opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. Dis Esophagus. 2015; 28: 196 ‐ 203.
dc.identifier.citedreferenceDiaz‐Cambronero O, Mazzinari G, Giner F, et al. Mu opioid receptor 1 (MOR‐1) expression in colorectal cancer and oncological long‐term outcomes: a five‐year retrospective longitudinal cohort study. Cancers (Basel). 2020; 12: 134.
dc.identifier.citedreferenceHatzoglou A, Bakogeorgou E, Kampa M, et al. Somatostatin and opioid receptors in mammary tissue. Role in cancer cell growth. Adv Exp Med Biol. 2000; 480: 55 ‐ 63.
dc.identifier.citedreferenceGach K, Szemraj J, Stasikowska‐Kanicka O, Danilewicz M, Janecka A. Opioid‐receptor gene expression and localization in cancer cells. Cent Eur J Biol. 2011; 6: 10 ‐ 15.
dc.identifier.citedreferenceLi C, Li L, Qin Y, et al. Exogenous morphine inhibits the growth of human gastric tumor in vivo. Ann Transl Med. 2020; 8: 385.
dc.identifier.citedreferenceJanku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016; 27: 2032 ‐ 2038.
dc.identifier.citedreferenceBimonte S, Barbieri A, Cascella M, et al. Naloxone counteracts the promoting tumor growth effects induced by morphine in an animal model of triple‐negative breast cancer. In Vivo. 2019; 33: 821 ‐ 825.
dc.identifier.citedreferenceBimonte S, Barbieri A, Rea D, et al. Morphine promotes tumor angiogenesis and increases breast cancer progression. Biomed Res Int. 2015; 2015: 161508.
dc.identifier.citedreferenceFriesen C, Roscher M, Alt A, Miltner E. Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Res. 2008; 68: 6059 ‐ 6064.
dc.identifier.citedreferenceManeckjee R, Minna JD. Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells. Proc Natl Adad Sci U S A. 1992; 89: 1169 ‐ 1173.
dc.identifier.citedreferenceRandall D, Degenhardt L, Vajdic CM, et al. Increasing cancer mortality among opioid‐dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health. 2011; 35: 220 ‐ 225.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33285.pdf
Size:
572.1KB
Format:
PDF
View/Open
Name:
cncr33285_am.pdf
Size:
498.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.